At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
CT-P59biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient With Mild Symptoms of SARS-CoV-2 Infection
In Brief
A Phase 1 clinical trial evaluating CT-P59 for SARS-CoV-2 Infection. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Virology of CT-P59 in Patient with Mild Symptoms of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection
CountriesSouth Korea
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedOct 2020
Primary CompletionOct 2020
Study CompletionApr 2021
TodayJul 2026
First PostedOct 20, 2020
Enrollment StartSep 4, 2020
Primary CompletionOct 26, 2020
Study CompletionApr 5, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.7 years ago
Interventions
CT-P59biological
administered